secwatch.observer — SEC 8-K summary
======================================

Issuer:     OnKure Therapeutics, Inc. (OKUR)
CIK:        0001637715
Form:       8-K
Filed at:   2023-05-03T23:59:59+00:00
Accession:  0001193125-23-134386
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reneo Pharma reports $93.8M cash; enters non-binding term sheet for up to $100M royalty financing
--------------------------------------------------------------------------------

- Preliminary cash, cash equivalents and short-term investments of $93.8M as of March 31, 2023.
- Non-binding term sheet for structured royalty financing up to $100M with an insider investor (>5% holder).
- Initial $30M at closing, additional tranches based on milestones; deal expected Q2 2023 if definitive.
- Collaboration agreement with affiliate development company; joint steering committee planned.
- Mavodelpar (REN001) royalty payments would apply if approved in US or EU.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1637715/000119312523134386/0001193125-23-134386-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1637715/000119312523134386/d133319d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-134386

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer